Effect-Site Target-Controlled Infusion in the Obese: Model Derivation and Performance Assessment

Simple item page
dc.contributor.authorCortínez, Luis
dc.contributor.authorSepúlveda, Pablo
dc.contributor.authorRolle, Augusto
dc.contributor.authorCottin, Pauline
dc.contributor.authorGuerrini, Alexandre
dc.contributor.authorAnderson, Brian J.
dc.date.accessioned2022-05-25T15:26:58Z
dc.date.available2022-05-25T15:26:58Z
dc.date.issued2018
dc.description.abstractBACKGROUND: The aim of this study is to derive a propofol pharmacokinetic (PK) pharmacodynamic (PD) model to perform effect-site target-controlled infusion (TCI) in obese patients, and to analyze its performance along with that of other available PK models. METHODS: In the first step of the study, a 3-compartment PK model linked to a sigmoidal inhibitory Emax PD model by a first-order rate constant (keo) was used to fit propofol concentration–bispectral index (BIS) data. Population modeling analysis was performed by nonlinear mixed effects regression in NONMEM (ICON, Dublin, Ireland). PK data from 3 previous studies in obese adult patients (n = 47), including PD (BIS) data from 1 of these studies (n = 20), were pooled and simultaneously analyzed. A decrease in NONMEM objective function (ΔOBJ) of 3.84 points, for an added parameter, was considered significant at the 0.05 level. In the second step of the study, we analyzed the predictive performance (median predictive errors [MDPE] and median absolute predictive errors [MDAPE]) of the current model and of other available models using an independent data set (n = 14). RESULTS: Step 1: The selected PKPD model produced an adequate fit of the data. Total body weight resulted in the best size scalar for volumes and clearances (ΔOBJ, −18.173). Empirical allometric total body weight relationships did not improve model fit (ΔOBJ, 0.309). A lag time parameter for BIS response improved the fit (ΔOBJ, 89.593). No effect of age or gender was observed. Step 2: Current model MDPE and MDAPE were 11.5% (3.7–25.0) and 26.8% (20.7–32.6) in the PK part and 0.4% (−10.39 to 3.85) and 11.9% (20.7–32.6) in the PD part. The PK model developed by Eleveld et al resulted in the lowest PK predictive errors (MDPE = <10% and MDAPE = <25%). CONCLUSIONS: We derived and validated a propofol PKPD model to perform effect-site TCI in obese patients. This model, derived exclusively from obese patient’s data, is not recommended for TCI in lean patients because it carries the risk of underdosing.es
dc.description.versionVersión Publicadaes
dc.identifier.citationCortínez, Luis I. MD*; Sepúlveda, Pablo MD†; Rolle, Augusto MD*; Cottin, Pauline PharmD‡; Guerrini, Alexandre PhD‡; Anderson, Brian J. PhD, FANZCA§ Effect-Site Target-Controlled Infusion in the Obese: Model Derivation and Performance Assessment, Anesthesia & Analgesia: October 2018 - Volume 127 - Issue 4 - p 865-872 doi: 10.1213/ANE.0000000000002814es
dc.identifier.urihttps://doi.org/10.1213/ANE.0000000000002814es
dc.identifier.urihttp://hdl.handle.net/11447/6136
dc.language.isoenes
dc.titleEffect-Site Target-Controlled Infusion in the Obese: Model Derivation and Performance Assessmentes
dc.typeArticlees
dcterms.sourceAnesthesia & Analgesiaes

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Effect_Site_Target_Controlled_Infusion_in_the.16.pdf
Size:
464.54 KB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services